Have you received REBYOTA to keep recurrent C. diff from coming back? SHARE YOUR STORY>


Keep recurrent C. diff infection from coming back with one dose of REBYOTATM

REBYOTA is the first and only single-dose, FDA approved microbiome-based treatment to keep recurrent C. diff infection from coming back, after you’ve already taken antibiotics.1

Flowers on a vine

This is Melissa’s Story

This is Melissa’s Story

Had this treatment been available sooner, I would have asked for it.

- Melissa, Clinical Study Patient

Watch Melissa’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Melissa was compensated for her time. Individual results may vary.

Melissa’s Story Video: Her Journey to REBYOTA Treatment

Have you also been treated with REBYOTA? SHARE YOUR STORY>

When a C. diff infection comes back, it’s called recurrent C. diff.

C. diff can be a gut-wrenching experience. Even after antibiotic treatment, for some people, it can come back more than once:

35% of people icon

Up to 35% of people who get a C. diff infection may have a recurrence2,3


65% of people icon

Up to 65% of people who experience a recurrence may have a second or third or more4,5


REBYOTA offers hope for people with recurrent C. diff.

Treatment With REBYOTA

An FDA approved microbiome-based treatment to keep recurrent C. diff infection from coming back after antibiotic treatment.

Treatment With REBYOTA

REBYOTA Support & Resources

Explore savings options, including how you may PAY AS LITTLE AS $100 for REBYOTA.a

Savings and Support
aTerms and conditions apply.
Flowers on a vine Flowers on a vine

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

What’s your experience with C. diff infection?*(Required)

*Required field.



  1. REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
  2. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States.  N Engl J Med. 2015;372(9):825-834.
  3. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(suppl 2):S154-S161.
  4. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(suppl 6):21-27.
  5. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020.

Please see Important Safety Information and full Prescribing Information


REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

  • You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
  • You should report to your doctor any infection you think you may have acquired after administration.
  • REBYOTA may contain food allergens.
  • Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
  • REBYOTA has not been studied in patients below 18 years of age.
  • Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information

You are leaving REBYOTA.com

The link you have selected will direct you to a site or resource outside of our website.
Thank you.